Clinical trials: Multiple Primary Neoplasm
Cystic Fibrosis, Primary Ciliary Dyskinesia
Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia
Cytobacteriological examination of sputum and bacteriological sampling in the middle meatus.
- Trial name
- BAVASI (NCT03494894)
- Testing
- Middle meatus aspirations and sputum
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004181
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Northwestern University
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Epilepsy, Tonic-Clonic
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
The purpose of this study is to evaluate the effectiveness and safety of an investigational new drug for supplemental therapy in subjects with primary generalized tonic-clonic (PGTC) seizures.
- Trial name
- NCT00043901
- Testing
- lamotrigine
- Where
- 87 sites in United States, Argentina and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Iliac Artery Stenosis
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System
The trial will be conducted to evaluate the safety and efficacy of the BeGraft Peripheral Stent Graft System in interventional revascularisation for subjects with primary iliac artery stenosis and/or occlusive lesions by…
- Trial name
- NCT04023370
- Testing
- Treatment of primary iliac artery stenosis and/or occlusive lesions
- Where
- 12 sites in China
- Volunteers
- 182 people
- Sponsor
- Bentley InnoMed GmbH
Multiple Myeloma, Plasma Cell Myeloma
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00064337
- Testing
- filgrastim, cyclophosphamide, dexamethasone
- Where
- 35 sites in United States
- Volunteers
- 104 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma and Plasma Cell Neoplasm
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients…
- Trial name
- NCT00003853
- Testing
- 4'-iodo-4'-deoxydoxorubicin
- Where
- 3 sites in United States, Italy
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
This study will assess safety as well as establish a Recommended Phase II dose of the combination of panobinostat and ruxolitinib in patients with or without the JAK2V617F mutation who have been diagnosed with primary…
- Conditions
- Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia-Vera Myelofibrosis
- Trial name
- NCT01433445
- Testing
- panobinostat, ruxolitinib
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- ReVIVE (NCT05359653)
- Testing
- Clemastine Fumarate
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Ichthyosis, Palmoplantar Keratoses
Reproductive Options in Inherited Skin Diseases
The goal of this observational study is to learn about the indications for prenatal diagnostics and preimplantation genetic testing for patients/couples affected by an inherited skin disease, and evaluate the clinical outcomes of…
- Conditions
- Ichthyosis, Palmoplantar Keratoses, Epidermolysis Bullosa, Ectodermal Dysplasia
- Trial name
- REPRO-ISD (NCT06330324)
- Where
- Netherlands
- Volunteers
- 650 people
- Sponsor
- Maastricht University Medical Center
Primary Progressive Nonfluent Aphasia
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia.
- Trial name
- AIDA (NCT03174886)
- Testing
- AADvac1 40 µg, AADvac1 160 µg
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Axon Neuroscience SE
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Cognitive Change, Motor Activity
Group Music Practice Enhances Development
This randomized controlled trial shows for the first time that focused musical instrumental practice as compared to traditional sensitization to music provokes multiple transfer effects in the cognitive and sensorimotor domain.
- Trial name
- OC (NCT04200794)
- Testing
- musical instrumental training, sensitization to music
- Where
- Switzerland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- School of Health Sciences Geneva
Hypertension, Pure Autonomic Failure
Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure
The purpose of this study is to test the hypothesis that angiotensin II plays a role in the supine hypertension of primary autonomic failure.
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy
- Trial name
- NCT01292694
- Testing
- Losartan, Captopril
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University
Immune Thrombocytopenic Purpura
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
- Trial name
- ITP (NCT02273960)
- Testing
- BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Full Thickness Rotator Cuff Tear
Pilot Study of Augment Rotator Cuff for Surgical Treatment of Full Thickness Rotator Cuff Tears
Study Purpose: To evaluate the safety and performance of Augment Rotator Cuff as a primary surgical treatment for full thickness rotator cuff tears.
- Trial name
- NCT01256242
- Testing
- Augment Rotator Cuff, Standard Suture Repair
- Where
- 4 sites in Canada
- Volunteers
- 31 people
- Sponsor
- BioMimetic Therapeutics
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L
Tuberous Sclerosis Complex, Seizures
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02544750
- Testing
- GWP42003-P
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
- Trial name
- NCT04159610
- Testing
- WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.